Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of BMS-986165 (deucravacitinib) in systemic lupus erythematosus
jRCT2080223712Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deucravacitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by Bristol Myers Squibb. Started Nov 2017; status: completed.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080223712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223712.